---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-031374"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2025-08-15T23:59:59+00:00"
generated_at: "2026-05-17T12:22:10.906287+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aquestive prices $85M common stock offering of 21.25M shares at $4.00/share

## Summary
- Offers 21.25M shares at $4.00/share; expected gross proceeds $85M, closing Aug 15, 2025.
- Proceeds to primarily fund launch/commercialization of Anaphylm (epinephrine sublingual film) pending FDA approval.
- Offering led by RTW Investments; includes Samsara BioCapital, EcoR1 Capital, Perceptive Advisors, others.
- Joint bookrunning managers: Leerink Partners, Cantor, Oppenheimer; H.C. Wainwright lead manager.

## SEC filing metadata
- accession: 0001140361-25-031374
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2025-08-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000114036125031374/0001140361-25-031374-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000114036125031374/ef20053945_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-031374
- JSON: https://secwatch.observer/filing/0001140361-25-031374.json
- Plain text: https://secwatch.observer/filing/0001140361-25-031374.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.